From Academic Kits to Platform Licensing

Four products, expanding margin over time. Start with research kits, grow into pharma platforms and IP royalties.

Product roadmap

First post-validation product

Sivoro Start

The research kit

Design complete, pending validation

Strain + scaffold kit for academic labs. Drop-in replacement for standard PDMS protocols. Includes engineered N. crassa strain, H-tree scaffold masters, growth media, and protocols.

✓ Engineered N. crassa strain ✓ H-tree scaffold masters ✓ Xylose growth media ✓ Protocol documentation ✓ Email support

Price point

$2,500 / kit

$500 reagent kit (20 assays)

Gross margin 70%

University research labs

Follows Start

Sivoro Organ

The pharma platform

Planned

Organ-on-chip integration targeting liver, gut, and blood-brain barrier models. Includes custom strain engineering and multi-year service contracts for pharma R&D teams.

✓ Organ-specific strain variants ✓ Co-culture integration ✓ Custom channel geometries ✓ Dedicated technical support ✓ Annual service contract

Price point

$50k–150k platform

$10k–30k annual service

Gross margin 60%

Pharma R&D

Follows Organ

Sivoro License

The IP stream

Planned

License Sivoro strain and valve IP to existing PDMS chip manufacturers. Non-exclusive royalties of 5–7%; exclusive arrangements at 10–12% plus upfront. Pure IP — lowest cost to deliver.

✓ Strain IP license ✓ Optogenetic valve IP ✓ Transfer package ✓ Field of use restrictions ✓ Sub-licensing rights

Price point

5–10% royalty

Exclusive: 10–12% + upfront

Gross margin 90%

Microfluidics OEMs

Long-term possibility

Sivoro Dx

Research-use-only assay formats

Not a current program

Research-use-only diagnostic formats for academic and pharma R&D. Clinical pathways are a long-term possibility and not a current program.

✓ RUO formats only ✓ Academic and pharma R&D ✓ Per-assay economics ✓ No clinical claims ✓ No regulatory program underway

Price point

Per-assay pricing

Subscription panel model

Gross margin 75%

Research use only

TAM Expansion

Each product tier unlocks a larger addressable market. Figures below are internal estimates, not third-party market research.

$500M Academic microfluidics
$2B Organ-on-chip by 2030
$5B PDMS replacement licensing

The total microfluidics market is the ceiling; Sivoro's living-chip position enables entry across all three segments sequentially.

Internal estimates. Segment sizing is derived from published market reports and our own assumptions about addressable share; treat these as directional rather than researched figures.

Three revenue streams, expanding margin over time

Stream 1

Academic Kits

First post-validation stream

70%

Sivoro Start kit: strain + scaffold + protocols. Recurring revenue from media replacements and strain upgrades.

$2,500 starter · $500 reagent kit (20 assays)

Stream 2

Pharma Platforms

Follows the kit

60%

Sivoro Organ platform with organ-chip integration. Custom strain engineering + service contracts.

$50k–150k platform · $10k–30k annual service

Stream 3

IP Licensing

Follows the platform

90%

License strain + valve IP to PDMS manufacturers. Pure IP — lowest cost to deliver.

Non-exclusive: 5–7% royalty · Exclusive: 10–12% + upfront

Modeled gross margins, pre-validation. The margin figures above (70%, 60%, 90%, 75%) are modeled from assumed unit economics, not observed from sales. No product has yet been built or sold.

Illustrative Revenue Mix, Third Year of Sales

40% Kits
30% Platforms
30% Licensing